CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/jhc.s456683
2024-05-30
Journal of Hepatocellular Carcinoma
Abstract:Fahreddin Palaz, 1, 2 Mehmet Ozsoz, 3 Ali Zarrinpar, 4, 5 Ilyas Sahin 5, 6 1 Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 2 Faculty of Medicine, Hacettepe University, Ankara, Turkey; 3 Department of Biomedical Engineering, Near East University, Nicosia, Turkey; 4 Department of Surgery, College of Medicine, University of Florida, Gainesville, FL, USA; 5 University of Florida Health Cancer Center, Gainesville, FL, USA; 6 Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA Correspondence: Ilyas Sahin, Email Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need for novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T cells to combat HCC. This review comprehensively assesses the applications of CRISPR systems in HCC treatment, focusing on in vivo targeting of cancer cells and the development of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-engineered T cells. We explore potential synergies between CRISPR-based cancer therapeutics and existing treatment options, discussing ongoing clinical trials and the role of CRISPR technology in improving HCC treatment outcomes with advanced safety measures. In summary, this review provides insights into the promising prospects and current challenges of using CRISPR technology in HCC treatment, with the ultimate goal of improving patient outcomes and revolutionizing the landscape of HCC therapeutics. Keywords: CRISPR, hepatocellular carcinoma, HCC, targeted cancer therapy, adoptive T cell immunotherapy, CAR T cell therapy Hepatocellular carcinoma (HCC) constitutes approximately 90% of primary liver cancers, a major global health concern, ranking as the third leading cause of cancer-related mortality worldwide. 1 For early-stage HCC, therapeutic options include surgical resection, ablation, and liver transplantation, while transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) is preferred for intermediate-stage cases. 2 However, unresectable disease affects a substantial portion of patients, with recurrence impacting up to 70% of those who have undergone tumor resection or ablation within 5 years. 3–5 Consequently, over 50% of HCC patients ultimately require systemic therapies, typically during the advanced disease stages. 4,6 HCC is resistant to conventional chemotherapy, leading to the use of targeted therapies such as sorafenib or lenvatinib (tyrosine kinase inhibitors, TKIs) as first-line treatments. Second-line therapy options include regorafenib (TKI), cabozantinib (TKI), or ramucirumab (anti-VEGFR2). 6,7 Notably, immunotherapy approaches utilizing immune checkpoint inhibitors (ICIs) have shown potent antitumor activity in recent studies. 8 Approved immunotherapy regimens now include first-line options like atezolizumab + bevacizumab (anti-PD-L1 + anti-VEGFA) or durvalumab + tremelimumab (anti-PD-L1 + anti-CTLA-4). For advanced HCC in the second-line setting, treatments consist of pembrolizumab (anti-PD-1) monotherapy or the combination of nivolumab + ipilimumab (anti-PD-1 + anti-CTLA-4). Additionally, numerous Phase III clinical trials are currently investigating novel agents and combination therapies. 6–9 Despite these notable advancements, outcomes for advanced HCC patients remain suboptimal. For instance, atezolizumab + bevacizumab yields an objective response rate (ORR) of 27% and a median overall survival of 19.2 months, while the novel combination of camrelizumab (anti-PD-1) and rivoceranib (apatinib, a TKI) shows an ORR of 34% and a median overall survival of 22.1 months. 10,11 Thus, the exploration of novel targeted therapies and immunotherapeutic approaches remains crucial for further improving the effectiveness of treatment. CRISPR-Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins) systems serve as RNA-guided adaptive immune mechanisms utilized by prokaryotes to defend against invading nucleic acids like bacteriophages. 12 The effector complex of a CRISPR system comprises one or more Cas proteins and a CRISPR-RNA (crRNA) that guides the effector complex to find and cleave a specific DNA or RNA sequence through base pairing. 13 As a bioengineering tool, CRISPR effector complexes can be easily and inexpensively reprogrammed to target different DNA or RNA sequences by simply modifying the -Abstract Truncated-
oncology